john mascarenhas

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (180)

• Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms
  Leukemia 2026 DOI: 10.1038/s41375-026-03115-w
  +Save
• Interferon in early MF: intersection of biology and evidence
  Blood Advances 2026 DOI: 10.1182/bloodadvances.2026020389
  +Save
• SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?
  Clinical Lymphoma Myeloma and Leukemia 2026 DOI: 10.1016/j.clml.2026.04.002
  +Save
• Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis
  Blood Advances 2026 DOI: 10.1182/bloodadvances.2025018695
  +Save
• Sequential treatment with ruxolitinib and imetelstat effectively depletes myelofibrosis hematopoietic stem and progenitor cells
  Leukemia 2026 DOI: 10.1038/s41375-026-02871-z
  +Save
• Interferon alpha in myeloproliferative neoplasms: evidence and practical considerations for clinical care
  Leukemia & Lymphoma 2026 DOI: 10.1080/10428194.2025.2594038
  +Save
• Acute Myeloid Leukemia, Myelodysplasia‐Related (AML‐MR), With del(5q) and Double Minutes Containing Chromosomal Segment 11q24 Leading to Amplification and Expression of FLI1
  Case Reports in Hematology 2026 DOI: 10.1155/crh/2250750
  +Save
• Supplementary Figure S1 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
  2025 DOI: 10.1158/1078-0432.30709681
  +Save
• Supplementary Figure S2 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
  2025 DOI: 10.1158/1078-0432.30709678
  +Save
• Supplementary Figure S3 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
  2025 DOI: 10.1158/1078-0432.30709675
  +Save